IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v35y2017i5d10.1007_s40273-017-0492-6.html
   My bibliography  Save this article

Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Author

Listed:
  • Christopher Carroll

    (School of Health and Related Research (ScHARR), University of Sheffield)

  • Paul Tappenden

    (School of Health and Related Research (ScHARR), University of Sheffield)

  • Rachid Rafia

    (School of Health and Related Research (ScHARR), University of Sheffield)

  • Jean Hamilton

    (School of Health and Related Research (ScHARR), University of Sheffield)

  • Duncan Chambers

    (School of Health and Related Research (ScHARR), University of Sheffield)

  • Mark Clowes

    (School of Health and Related Research (ScHARR), University of Sheffield)

  • Paul Durrington

    (University of Manchester)

  • Nadeem Qureshi

    (University of Nottingham)

  • Anthony S. Wierzbicki

Abstract

As part of its single technology appraisal (STA) process, the UK National Institute for Health and Care Excellence (NICE) invited the manufacturer of evolocumab (Amgen) to submit evidence on the clinical and cost effectiveness of evolocumab. The appraisal assessed evolocumab as monotherapy or in combination with a statin with or without ezetimibe, or in combination with ezetimibe (without statin therapy), in adult patients with primary hypercholesterolaemia (which includes mixed dyslipidaemia), for whom statins do not provide optimal control of their low-density lipoprotein cholesterol (LDL-C) levels and/or for whom statins are contraindicated or not tolerated. The School of Health and Related Research Technology Appraisal Group at the University of Sheffield was commissioned to act as the independent Evidence Review Group (ERG). The ERG produced a critical review of the evidence for the clinical and cost effectiveness of the technology based on the company’s submission to NICE. The evidence was derived mainly from four randomised controlled trials comparing evolocumab with either ezetimibe or placebo in adults with primary familial or non-familial hypercholesterolaemia, who were either able to take statins or who were statin intolerant. The clinical-effectiveness review found that evolocumab is efficacious at lowering LDL-C but that there was uncertainty regarding its impact on cardiovascular disease (CVD) outcomes. In response to the ERG’s critique of the submitted health economic model, the company submitted an amended model, which also included a patient access scheme (PAS). Based on this, the deterministic incremental cost-effectiveness ratios (ICERs) for evolocumab against ezetimibe were above £74,000 and £45,000 per quality-adjusted life-year (QALY) gained within the non-familial primary and secondary prevention populations, respectively, whilst the ICER within the heterozygous familial hypercholesterolaemia (HeFH) population was approximately £23,000 per QALY gained. The final determination was that evolocumab would be a clinically and cost-effective use of UK NHS resource in certain patient subgroups.

Suggested Citation

  • Christopher Carroll & Paul Tappenden & Rachid Rafia & Jean Hamilton & Duncan Chambers & Mark Clowes & Paul Durrington & Nadeem Qureshi & Anthony S. Wierzbicki, 2017. "Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 35(5), pages 537-547, May.
    • Handle: RePEc:spr:pharme:v:35:y:2017:i:5:d:10.1007_s40273-017-0492-6
    DOI: 10.1007/s40273-017-0492-6
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-017-0492-6
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40273-017-0492-6?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Unknown, 2016. "Department Publications 2014," Publications Lists 239845, University of Minnesota, Department of Applied Economics.
    2. Unknown, 2014. "Department Publications 2013," Publications Lists 206935, University of Minnesota, Department of Applied Economics.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Robert Koulish, 2016. "Using Risk to Assess the Legal Violence of Mandatory Detention," Laws, MDPI, vol. 5(3), pages 1-20, July.
    2. Morgan, Kimberly L. & Interis, Matthew G., 2017. "Who Buys More Directly from Producers in the Southeastern United States? A Research Note," Journal of Food Distribution Research, Food Distribution Research Society, vol. 48(2), July.
    3. A. Duarte & C. Bojke & W. Cayton & A. Salawu & B. Case & L. Bojke & G. Richardson, 2018. "Impact of specialist rehabilitation services on hospital length of stay and associated costs," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(7), pages 1027-1034, September.
    4. C Alexiou & J G Nellis, 2016. "A post-mortem of austerity: the Greek experience," Economic Issues Journal Articles, Economic Issues, vol. 21(2), pages 1-32, September.
    5. Paul Tappenden & Christopher Carroll & John W. Stevens & Andrew Rawdin & Sabine Grimm & Mark Clowes & Eva Kaltenthaler & John R. Ingram & Fiona Collier & Mohammad Ghazavi, 2017. "Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 35(8), pages 805-815, August.
    6. Hazel Squires & Abdullah Pandor & Praveen Thokala & John W. Stevens & Eva Kaltenthaler & Mark Clowes & Robert Coleman & Lynda Wyld, 2018. "Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 36(1), pages 29-38, January.
    7. Kaplan, Jonathan D. & Norton, Max & Baumgartner, Kendra, 2018. "An ounce of prevention and a pound of cure: the substitutability or complementarity of grapevine trunk disease management practices," 2018 Annual Meeting, August 5-7, Washington, D.C. 274361, Agricultural and Applied Economics Association.
    8. Kim Loader, 2018. "Small- and medium-sized enterprises and public procurement: A review of the UK coalition government's policies and their impact," Environment and Planning C, , vol. 36(1), pages 47-66, February.
    9. Jacopo Arpetti & Antonio Iovanella, 2019. "Towards more effective consumer steering via network analysis," Papers 1903.11469, arXiv.org, revised Nov 2019.
    10. Jeremy Greenwood & Nezih Guner & Guillaume Vandenbroucke, 2017. "Family Economics Writ Large," Journal of Economic Literature, American Economic Association, vol. 55(4), pages 1346-1434, December.
    11. Mai, Nhat Chi, 2022. "Capital Raising and Management of Vietnamese Small and Medium Sized Enterprises after Integrating into Global Economy," OSF Preprints dv68m, Center for Open Science.
    12. Kate Golebiowska, 2016. "Are Peripheral Regions Benefiting from National Policies Aimed at Attracting Skilled Migrants? Case Study of the Northern Territory of Australia," Journal of International Migration and Integration, Springer, vol. 17(3), pages 947-971, August.
    13. Andrew Cleves & Paul Dimmock & Neil Hewitt & Grace Carolan-Rees, 2016. "The TURis System for Transurethral Resection of the Prostate: A NICE Medical Technology Guidance," Applied Health Economics and Health Policy, Springer, vol. 14(3), pages 267-279, June.
    14. Hongxing Liu & Wendong Zhang & Elena Irwin & Jeffrey Kast & Noel Aloysius & Jay Martin & Margaret Kalcic, 2020. "Best Management Practices and Nutrient Reduction: An Integrated Economic-Hydrologic Model of the Western Lake Erie Basin," Land Economics, University of Wisconsin Press, vol. 96(4), pages 510-530.
    15. Oliveira, Victor & Frazao, Elizabeth, 2015. "The WIC Program: Background, Trends, and Economic Issues, 2015 Edition," Economic Information Bulletin 197543, United States Department of Agriculture, Economic Research Service.
    16. Böhm, Sebastian & Grossmann, Volker & Strulik, Holger, 2021. "R&D-driven medical progress, health care costs, and the future of human longevity," The Journal of the Economics of Ageing, Elsevier, vol. 18(C).
    17. Evelina A. Zimovetz & Alain Joseph & Rajeev Ayyagari & Josephine A. Mauskopf, 2018. "A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(1), pages 21-35, January.
    18. Mehri , N. & Messkoub, M. & Kunkel, S., 2019. "Trends, determinants and the implications of population aging in Iran," ISS Working Papers - General Series 646, International Institute of Social Studies of Erasmus University Rotterdam (ISS), The Hague.
    19. Mahdi Gharaibeh & Ali McBride & David S. Alberts & Brian Erstad & Marion Slack & Nimer Alsaid & J. Lyle Bootman & Ivo Abraham, 2018. "Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer," PharmacoEconomics, Springer, vol. 36(11), pages 1333-1343, November.
    20. Paul Cheshire & Stephen Gibbons & Jemma Mouland, 2017. "Social Tenants' Health: Evaluating the Effectiveness of Landlord Interventions," SERC Discussion Papers 0219, Centre for Economic Performance, LSE.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:35:y:2017:i:5:d:10.1007_s40273-017-0492-6. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.